Clinical Drug-Drug Interaction Profile Of BIA 28-6156: Results From Three Independent Phase I Studies
Objective: Three independent, open-label, clinical drug-drug interaction (DDI) studies were conducted to characterise the clinical DDI profile of BIA 28-6156. Background: BIA 28-6156 (paricerat) is…Age-Related Hearing Loss in Idiopathic Parkinson’s Disease and APOE E4 Carriers
Objective: Identify whether APOE E4 modulates the relationship between age and hearing loss in idiopathic Parkinson’s disease (PD). Background: Hearing loss is associated with increased…Integrative Analysis of GBA1 Mutations and GCase Deficiency in Parkinson’s Disease using Long Read Nanopore Sequencing
Objective: To sequence the GBA1 gene in PD patients with reduced GCase activity using nanopore amplicon-targeted sequencing.To characterize benign, VUS, and pathogenic GBA1 variants. Background:…Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s disease: Findings From the PADOVA Phase IIb Study
Objective: To evaluate the effects of prasinezumab on neuroimaging biomarkers in individuals with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: PD is characterized by the…Continuous Subcutaneous Apomorphine Infusion in Parkinson Disease: Final Data from the Multi-Year InfusON Open-Label Extension Study
Objective: Report outcomes from the multi-year extension to the 52-week open-label InfusON study (NCT02339064)1 of continuous subcutaneous apomorphine infusion (CSAI). Background: The US phase 3…Impact of Amyloid-beta co-pathology on future hallucination in Parkinson’s disease
Objective: To investigate whether baseline amyloid-β positivity is associated with subsequent development of major hallucination in Parkinson’s disease (PD). Background: Hallucinations are a major non-motor complication…Quantitative Neurodegenerative Risk Modelling and Clinical Score Prediction Using Mixed Reality
Objective: This study investigates the potential of mixed reality (MR) tool for multimodal data collection from individuals with Parkinson’s disease and examines the use of…Characteristics and Outcomes of Hospitalisation Episodes for Australians living with Parkinson’s Disease
Objective: To examine the characteristics and outcomes of acute inpatient hospitalisation episodes for people with Parkinson’s disease (PD) living in Victoria, Australia. Background: People with…Mitochondrial Density Shapes Regional Vulnerability to Atrophy in Parkinson’s Disease
Objective: To characterise the coupling between regional mitochondrial density and complex I activity and spatially patterned brain atrophy in Parkinson's disease (PD), and its variation…One-Year Trajectories of Non-Motor Symptoms in Parkinson’s Disease: A Longitudinal Cohort Study Using the MDS-NMS with Age at Onset Stratification
Objective: To characterise one-year non-motor symptom (NMS) trajectories in Parkinson’s disease (PD) stratified by age at onset (AAO) (EOPD ≤50 years; LOPD >50 years). Background:…
- « Previous Page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- …
- 553
- Next Page »